Specific Effect of BRAF-Inhibitors on a BRAF-mutant and a Wild-type Cell Line of Malignant Melanoma

被引：0
作者：
Steck, M. [1 ]
Grabenbauer, M. [1 ]
Fuenfle, R. [1 ]
Hecht, M. [1 ]
Fietkau, R. [1 ]
Distel, L., V [1 ]
机构：
[1] Friedrich Alexander Univ Erlangen Nurnberg, Strahlenklin, Erlangen, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2017年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P22-5-jD
引用
收藏
页码：S169 / S170
页数：2
相关论文
共 50 条
  • [41] Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients
    Saint-Jean, Melanie
    Quereux, Gaelle
    Nguyen, Man-Michel
    Peuvrel, Lucie
    Brocard, Anabelle
    Vallee, Audrey
    Knol, Anne-Chantal
    Khammari, Amir
    Denis, Marc G.
    Dreno, Brigitte
    ONCOLOGY REPORTS, 2014, 32 (02) : 808 - 814
  • [42] CD8+T-cell distribution and immunomodulator expression in BRAF-mutant melanoma affect the response to BRAF inhibitor and chemotherapy
    Wongchenko, Matthew
    Rabe, Christina
    Sosman, Jeffrey
    McArthur, Grant
    Xiao, Yuanyuan
    Gilbert, Houston
    Andries, Luc
    Kockx, Mark
    Koeppen, Hartmut
    Hegde, Priti
    Amler, Lukas
    Yan, Yibing
    Ribas, Antoni
    CANCER RESEARCH, 2015, 75
  • [43] Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials
    Larkin, James
    Lao, Christopher D.
    Urba, Walter J.
    McDermott, David F.
    Horak, Christine
    Jiang, Joel
    Wolchok, Jedd D.
    JAMA ONCOLOGY, 2015, 1 (04) : 433 - 440
  • [44] Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells
    Rotolo, S
    Diotti, R
    Gordon, RE
    Qiao, RF
    Yao, Z
    Phelps, RG
    Dong, JL
    INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (01) : 164 - 169
  • [45] Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
    Deborah JL Wong
    Lidia Robert
    Mohammad S Atefi
    Amanda Lassen
    Geetha Avarappatt
    Michael Cerniglia
    Earl Avramis
    Jennifer Tsoi
    David Foulad
    Thomas G Graeber
    Begonya Comin-Anduix
    Ahmed Samatar
    Roger S Lo
    Antoni Ribas
    Molecular Cancer, 14
  • [46] A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
    Tarhini, A. A.
    Toor, K.
    Chan, K.
    McDermott, D. F.
    Mohr, P.
    Larkin, J.
    Hodi, F. S.
    Lee, C-H
    Rizzo, J., I
    Johnson, H.
    Moshyk, A.
    Rao, S.
    Kotapati, S.
    Atkins, M. B.
    ESMO OPEN, 2021, 6 (02)
  • [47] Effectiveness of immunotherapy versus BRAF/MEK inhibitors in treatment-naive BRAF-mutant advanced melanoma: A single institution retrospective analysis.
    Ahmed, Mamoon
    Abdullah, Hafez M.
    Ali, Mohammad
    Morris, Kahlen
    Sathyanarayanan, Swaminathan Perinkulam Perinkulam
    Ali, Lina
    Gurumoorthy, Aarabhi
    Bleeker, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma
    Haugh, Alexandra
    Daud, Adil I.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (03) : 407 - 419
  • [49] Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma
    Alexandra Haugh
    Adil I. Daud
    American Journal of Clinical Dermatology, 2024, 25 : 407 - 419
  • [50] Role of IGF1R in mediating resistance to MAPK pathway inhibitors in BRAF-mutant melanoma
    Patel, Hima
    Mishra, Rosalin
    Broit, Natasa
    Yacoub, Nour
    Yuan, Long
    Alanazi, Samar
    Hayward, Nicholas
    Johansson, Peter
    Garrett, Joan T.
    CANCER RESEARCH, 2020, 80 (16)
12345